Literature DB >> 2179501

Natural killer cytotoxicity in the diagnosis of immune dysfunction: criteria for a reproducible assay.

T L Whiteside1, J Bryant, R Day, R B Herberman.   

Abstract

Current evidence indicates that natural killer (NK) cells, which are large granular lymphocytes that mediate non-major histocompatibility complex (MHC)-restricted cytotoxicity and antibody-dependent cytotoxicity and that are involved in multiple regulatory, developmental, and immunologic processes, are important in health. Immunodeficiency states presenting with low NK activity are often associated with malignancies, chronic viral infections, or autoimmune diseases. Monitoring of NK function appears to be indicated as an aid to diagnosis, prognosis, and follow-up after therapy. Reliable performance of NK assays in a clinical laboratory requires that uniform criteria be established and followed for the acceptability of results. Statistical analysis of daily variability can be of great assistance in identifying and tracking sources of error, but routine statistical adjustments are not generally advisable. The quality control program described here provides a degree of assurance that this cytotoxicity assay can be dependable whether performed at one time point or serially. The successful implementation of this program requires laboratory resources, biostatistical support, and interpretative skills, all of which are available in a modern clinical laboratory.

Entities:  

Mesh:

Year:  1990        PMID: 2179501     DOI: 10.1002/jcla.1860040207

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   2.352


  27 in total

Review 1.  Monitoring of antigen-specific cytolytic T lymphocytes in cancer patients receiving immunotherapy.

Authors:  T L Whiteside
Journal:  Clin Diagn Lab Immunol       Date:  2000-05

2.  Immune function in female elite rowers and non-athletes.

Authors:  D C Nieman; S L Nehlsen-Cannarella; O R Fagoaga; D A Henson; M Shannon; J M Hjertman; R L Schmitt; M R Bolton; M D Austin; B K Schilling; R Thorpe
Journal:  Br J Sports Med       Date:  2000-06       Impact factor: 13.800

3.  Evaluation of natural killer cell activity.

Authors:  J H Cox; M deSouza
Journal:  Mol Biotechnol       Date:  2000-06       Impact factor: 2.695

4.  IRX-2, a novel immunotherapeutic, enhances and protects NK-cell functions in cancer patients.

Authors:  B Schilling; E S Halstead; P Schuler; M Harasymczuk; J E Egan; T L Whiteside
Journal:  Cancer Immunol Immunother       Date:  2012-01-20       Impact factor: 6.968

5.  Evaluation of the modified ELISPOT assay for gamma interferon production in cancer patients receiving antitumor vaccines.

Authors:  T Asai; W J Storkus; T L Whiteside
Journal:  Clin Diagn Lab Immunol       Date:  2000-03

6.  Improving methods of assessing natural killer cell cytotoxicity.

Authors:  Sandra E Sephton; Helena C Kraemer; Eric Neri; Daniel P Stites; Inka Weissbecker; David Spiegel
Journal:  Int J Methods Psychiatr Res       Date:  2006       Impact factor: 4.035

7.  Serial monitoring of immunologic function and phenotype of lymphocytes in the blood of transplanted patients randomized to cyclosporine or FK 506.

Authors:  T L Whiteside; J Wilson; J Bryant; A Zeevi; K Abu el-Magd; A Jain; M Alessiani; J Fung; R B Herberman; T E Starzl
Journal:  Transplant Proc       Date:  1991-12       Impact factor: 1.066

8.  Effects of nitrogen oxides on natural killer cells in glass craftsmen and braziers.

Authors:  M R Azari; F M Williams; J Kirby; P Kelly; J W Edwards; P G Blain
Journal:  Occup Environ Med       Date:  1996-04       Impact factor: 4.402

9.  The impact of sleep complaints on physical health and immune outcomes in rescue workers: a 1-year prospective study.

Authors:  Leah A Irish; Angela L Dougall; Douglas L Delahanty; Martica H Hall
Journal:  Psychosom Med       Date:  2013-01-16       Impact factor: 4.312

10.  Inflammatory cell infiltrate in a responding metastatic nodule after vaccine-based immunotherapy.

Authors:  T F Logan; B Banner; U Rao; M S Ernstoff; N Wolmark; T L Whiteside; L Miketic; J M Kirkwood
Journal:  Clin Exp Immunol       Date:  1998-12       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.